Alexandros Sianis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alexandros Sianis has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Alexandros Briasoulis
Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
1 shared publication - Angeliki M. Chasouraki
Internal Medicine Clinic, Pammakaristos Hospital of Divine Providence (Reference Centre for COVID-19 Infection), Athens, Greece
1 shared publication - Argyrios Ntalianis
Department of Therapeutics, Alexandra University Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece
1 shared publication - Christos Kourek
Clinical Ergospirometry, Exercise and Rehabilitation Laboratory, National and Kapodistrian University of Athens, 106 75 Athens, Greece
1 shared publication - Ioannis Paraskevaidis
Medical School of Athens, National and Kapodistrian University of Athens, 11527 Athens, Greece
1 shared publication - Nikolaos Panagiotou
Department of Clinical Therapeutics, National Kapodistrian University of Athens, 11528 Athens, Greece
1 shared publication
Latest Publications
- Open Access
- 23 February 2022
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 9 (3) , 66
Cardiotoxicity of Non-Anthracycline Cancer Chemotherapy Agents
Throughout the last decades, newly developed chemotherapeutic agents and immunotherapies that target signaling pathways have provided patients with better prognoses, improved their quality of life and increased survival rates, thus converting cancer to a stable chronic disease. However, non-anthracycline cancer chemotherapy agents and immunotherapies including human epidermal growth factor receptor 2 (HER2) inhibitors, vascular endothelial growth factor (VEGF) inhibitors, Bcr-Abl tyrosine-kinase inhibitors (TKI), proteasome inhibitors, immune checkpoint inhibitors and chimeric antigen receptor T cells (CAR-T cells) may cause cardiovascular toxicity events and complications that usually interrupt the continuation of an appropriate treatment regimen, which induces life-threatening risks or leads to long-term morbidity. Heart failure, cardiac arrythmias and cardiomyopathies are the most common cardiovascular events related to cardiotoxicity due to chemotherapy. Each patient should be carefully assessed and monitored before, during and after the administration of chemotherapy, to address any predisposing risk factors and the new onset of cardiotoxicity manifestations early and treat them appropriately. The development of novel anticancer agents that cause minimal cardiovascular toxicity events or novel agents that ameliorate the adverse effects of the existing anticancer agents could drastically change the field of cardio-oncology. The aim of this narrative review is to demonstrate new knowledge regarding the screening and diagnosis of non-anthracycline-induced cardiotoxicity and to propose protective measures that could be performed in order to achieve the delivery of optimal care.
- 23 February 2022
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 9 (3) , 66
Open AccessCardiotoxicity of Non-Anthracycline Cancer Chemotherapy Agents
Throughout the last decades, newly developed chemotherapeutic agents and immunotherapies that target signaling pathways have provided patients with better prognoses, improved their quality of life and increased survival rates, thus converting cancer to a stable chronic disease. However, non-anthracycline cancer chemotherapy agents and immunotherapies including human epidermal growth factor receptor 2 (HER2) inhibitors, vascular endothelial growth factor (VEGF) inhibitors, Bcr-Abl tyrosine-kinase inhibitors (TKI), proteasome inhibitors, immune checkpoint inhibitors and chimeric antigen receptor T cells (CAR-T cells) may cause cardiovascular toxicity events and complications that usually interrupt the continuation of an appropriate treatment regimen, which induces life-threatening risks or leads to long-term morbidity. Heart failure, cardiac arrythmias and cardiomyopathies are the most common cardiovascular events related to cardiotoxicity due to chemotherapy. Each patient should be carefully assessed and monitored before, during and after the administration of chemotherapy, to address any predisposing risk factors and the new onset of cardiotoxicity manifestations early and treat them appropriately. The development of novel anticancer agents that cause minimal cardiovascular toxicity events or novel agents that ameliorate the adverse effects of the existing anticancer agents could drastically change the field of cardio-oncology. The aim of this narrative review is to demonstrate new knowledge regarding the screening and diagnosis of non-anthracycline-induced cardiotoxicity and to propose protective measures that could be performed in order to achieve the delivery of optimal care.